2025-523996-45-00RecruitingPhase 4
The POST-PRANDIAL HYPO-AVOID STUDY Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People with Type 1 Diabetes
Source: EU CTIS (euclinicaltrials.eu) · Last updated 16 Mar 2026
Brief summary (registry, in English)
To evaluate whether pre-exercise administration of low-dose subcutaneous glucagon prevents or attenuates exercise-induced declines in plasma glucose concentration during and after moderate-intensity continuous exercise (MICE) performed approximately 90 minutes after a meal in adults with type 1 diabetes using an automated insulin delivery (AID) system.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 14 Jan 2026
- Start date
- 10 Apr 2026
- Lead sponsor
- Steno Diabetes Center Copenhagen
- Diseases
- Type 1 diabetes
- EU CT number
- 2025-523996-45-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 18
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 diabetes who use an automated insulin delivery system. It tests low-dose glucagon before exercise after a meal.
- Age
- Older than 18 years
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes for more than 2 years.
- Earlier treatment
- Must have used an automated insulin delivery system for 3 months or more. Must have been treated with NovoRapid or Fiasp for at least one week before joining.
Main reasons for not taking part
- Allergy or past allergic reaction to lactose or glucagon
- Pheochromocytoma, insulinoma or gastroparesis
- Women of childbearing age who are pregnant, breast-feeding, planning pregnancy or not using adequate contraception
- Other medical or psychological conditions that the investigator judges make taking part unsuitable
- Cannot understand the information or give informed consent
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (methods are considered adequate for study enrolment for females: an intrauterine device, hormonal contraception (birth control pills, implant, patch, vaginal ring or injection), a single partner who is sterile or infertile, or sexual abstinence. Contraception is required throughout the study duration. Sterilized or postmenopausal women (>12 months since last period) are not required to use contraception)
Other illness
- Allergies to lactose or glucagon
- Known or suspected allergies to glucagon or related products
- History of hypersensitivity or allergic reaction to glucagon or lactose
Lab values
- Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation
Other
- Patients with diagnosed pheochromocytoma, insulinoma or gastroparesis
- Lack of compliance with key study procedures at the discretion of the investigator
- Inability to understand the individual information and to give informed consent
Who the study is looking for
- Age more than 18 years old
- Type 1 diabetes > 2 years
- Use of automated insulin delivery system for equal to or more than 3 months
- Treated with NovoRapid or Fiasp for at least one week priro to enrolment
- Proefficiency in carbohydrate counting
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Steno Diabetes Center Copenhagen | Herlev | Denmark | Recruiting |
The registry text, word for word
This page is information, not medical advice. Discuss any trial with your doctor.